Thesis formulates customized nootropic supplements that target specific cognitive states using blends such as Energy, Clarity and Motivation. Its products use clinically studied active ingredients with high bioavailability and are manufactured to FDA cGMP standards. The brand emphasizes a digital-first, education-focused model and positions customization as its core differentiator in the wellness category. Founder and CEO Dan Freed developed the approach to help people optimize cognitive performance. Thesis has raised over $13.5M to date, including a recent $8.4M Series A and a prior $5.1M seed. The new capital will be used for key executive hires, product expansion and clinical trials.

Total raised

$8M

Funding rounds

1

Latest round

Series A

Latest activity

May 2023